Acadian Asset Management
TVRD

Acadian Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Acadian Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-281
Closed -$5K – 1846
2024
Q4 		$5K Sell
281
-983
-78% -$10.7K ﹤0.01% 1572
2024
Q3 		$13K Sell
1,264
-6,161
-83% -$72.2K ﹤0.01% 2019
2024
Q2 		$68K Sell
7,425
-1,859
-20% -$44.3K ﹤0.01% 1578
2024
Q1 		$303K Sell
9,284
-729
-7% -$18.9K ﹤0.01% 1113
2023
Q4 		$266K Buy
10,013
+3,661
+58% +$152K ﹤0.01% 1177
2023
Q3 		$383K Buy
+6,352
New +$596K ﹤0.01% 1074
2021
Q3 		– Sell
-853
Closed -$438K – 2068
2021
Q2 		$438K Buy
853
+669
+364% +$424K ﹤0.01% 1193
2021
Q1 		$145K Buy
+184
New +$126K ﹤0.01% 1587

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management's TVRD Position: Q1 2025 in Review

Acadian Asset Management sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 281 shares — an estimated $5K sold.

Acadian Asset Management first reported a position in TVRD in Q1 2021 and held it in 8 quarters. The position peaked at $438K in Q2 2021. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

  • Acadian Asset Management reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 281 Tvardi Therapeutics shares in Q1 2025, an estimated $5K.
  • Acadian Asset Management first reported a position in Tvardi Therapeutics in Q1 2021 and held it in 8 quarters.
  • Acadian Asset Management's Tvardi Therapeutics position peaked at $438K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.